Physician profile
Melissa Haggerty
NPI 1881236016
$8,828.06
in general payments reported to CMS, 2019-2025
63 companies · $96.70 in 2025
The $96.70 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.45 · 2021: $3,380 · 2022: $3,859 · 2023: $582 · 2024: $891 · 2025: $96.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.42 |
| Education | $181.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,387.54 | 2021-2025 | Opdivo, Augtyro |
| Seagen INC. | $760.48 | 2021-2023 | Tukysa |
| Janssen Biotech, INC. | $541.80 | 2021-2022 | |
| Incyte Corporation | $513.29 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $461.45 | 2021-2024 | Imfinzi, Lynparza, Calquence |
| Novartis Pharmaceuticals Corporation | $414.24 | 2021-2022 | |
| Daiichi Sankyo INC. | $355.89 | 2021-2022 | |
| Pfizer INC. | $311.41 | 2021-2024 | |
| Astellas Pharma US INC | $262.59 | 2021-2022 | |
| Abbvie INC. | $262.09 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $230.11 | 2021-2022 | |
| Genzyme Corporation | $229.70 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $197.02 | 2021-2022 | |
| Celgene Corporation | $184.09 | 2021-2022 | |
| Kite Pharma, INC. | $150.53 | 2021-2023 | Yescarta |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Haggerty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.